Tuesday 21-07-2020 Post #17 FarmaKology
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “[email protected]”, and happy to have you featured on our newsletter (+6666 Subscribers )!
Issue #50 Issue #51
News
IU School of Medicine announces an agreement with Lilly for autoimmune disease research
Indiana University School of Medicine announced today a strategic research agreement with Eli Lilly and Company designed to ultimately benefit people suffering from a variety of autoimmune diseases. The five-year, $5 million deal will span multiple projects and teams. The purpose of the agreement is to gain an understanding of the molecular and cellular changes which occur in patients after administration of some of Lilly's currently marketed autoimmune therapies that are also being developed for the potential of new autoimmune diseases, including inflammatory bowel disease and psoriasis.
Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced it has dosed its first patient in a Phase 1/2 study of the Company's proprietary IL12 investigational immunotherapy, DF6002. Dragonfly's DF6002 clinical trial is currently recruiting patients with advanced solid tumours at Lifespan Cancer Institute at Rhode Island Hospital, the principal teaching hospital of Brown University, with additional sites scheduled to open shortly. DF6002 will be Dragonfly's second drug in the clinic, with its NK cell engager therapy DF1001 having started clinical testing in the fall of 2019.
Evotec enters partnership with QUANTRO Therapeutics
Evotec SE announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. QUANTRO will combine and exploit innovative functional-genetic and transcriptomic technologies to generate an unprecedented drug discovery pipeline transforming the precision and scope of cell-based compound screens. By introducing “Transcriptional Fingerprinting” to drug discovery,
BioNTech plans share sale with Pfizer logging large order
German biotech company BioNTech said on Tuesday it plans to raise cash in a share sale that will see its coronavirus vaccine partner Pfizer Inc become a shareholder. The rights offering announcement is the latest in a flurry of financing activity this week around German biotech companies that are racing to develop potential vaccines against the novel coronavirus. Shares in BioNTech, whose market capitalisation stands at $21 billion, surged 7% to $94.47 by 1400 GMT. BioNTech said in a statement it planned to sell 5 million shares - worth $472 million at current market prices - and that Pfizer logged an order worth $200 million in shares.
Research & Study
Immunotherapy Appears Safe for Cancer Patients with COVID-19
IBM Research develops new macromolecule that could counter antibiotic resistance
Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Upcoming Webinar
Give ‘Em a Hand! - A Happi Hand Hygiene Webinar
Driving Operational Agility with Digital Quality Management
Best Practices for HR in Pharma During Uncertain Times
Video
